DISC-3405

DRUG3 trials

Sponsors

Disc Medicine, Inc

Conditions

Healthy VolunteerPolycythemia Vera (PV)Sickle Cell Disease

Phase 1

A Study of DISC-3405 in Healthy Volunteers

CompletedNCT06050915

Disc Medicine, IncHealthy Volunteer

Start: 2023-10-03End: 2024-07-09Updated: 2024-12-18

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

RecruitingNCT07187973

Disc Medicine, IncSickle Cell Disease

Start: 2026-01-06End: 2027-10-01Target: 24Updated: 2026-09-16

Phase 2

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Active, not recruitingNCT06985147

Disc Medicine, IncPolycythemia Vera (PV)

Start: 2025-08-12End: 2029-02-01Target: 60Updated: 2026-07-31

Related Papers

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood2025-11-03

Pharmacological Inhibition of TMPRSS6 Decreases Hemoglobin Concentration and Red Blood Cell (RBC) Hemolysis in a Mouse Model of Sickle Cell Disease

Blood2024-11-05